A combination of the Bristol-Myers Squibb Co. checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) diminished the size of previously untreated renal cell carcinomas (RCC) for more people than Pfizer Inc.'s Sutent (sunitinib) during a closely watched phase III trial. Read More
The explosive growth of type 2 diabetes (T2D) is well-known, as are the reasons for its alarming prevalence. T2D now touches every age cohort and nearly every culture in every corner of the world, driving corresponding increases in complications such as stroke, blindness, kidney disease and skin ulcers, with debilitating or deadly results. Read More
HONG KONG – As the incidence of diabetes in China continues to climb to alarming rates, multinational and local pharmaceutical companies are racing to take a larger slice of the growing market pie, but patients in lower-tier cities will have to wait before they can access innovative treatments. Read More
When the FDA recently gave drug manufacturers a one-year grace period on complying with the Nov. 27 serialization requirements of the Drug Supply Chain Security Act (DSCSA), a lot of companies likely heaved a sigh of relief. Read More
Comparative sequencing of primary breast tumors and metastases has revealed that the cells that seed metastases break off from the primary tumor relatively late in tumor development, and as a result, are usually genetically similar to the primary tumor at the time of diagnosis. Read More
Dynavax Technologies Corp. raised net proceeds of about $64.5 million through a public offering of 27.6 million shares of its common stock, including 3.6 million shares sold to its underwriters. Read More
Aslan Pharmaceuticals Pte. Ltd., of Singapore, inked a research collaborative agreement with the Academia Sinica Genomic Research Centre, of Taiwan. Read More
Achieve Life Sciences Inc., of Bothell, Wash., said it initiated the development program for its smoking cessation candidate, cytisine, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor that is approved and marketed in Central and Eastern Europe. Read More
